Overall and progression-free survival in patients with primary lung adenocarcinoma expressing two or more biomarkers: a systematic review of the literature
Cargando...
Fecha
2023
Título de la revista
Publicado en
Publicado por
URL de la fuente
ISSN de la revista
Título del volumen
Resumen
Introduction: Lung cancer is one of the most prevalent types of malignancy and a leading cause of cancer-related death. Substantial improvements in the understanding of disease biology, the refinement of therapeutic approaches, and the implementation of predictive biomarkers for treatment selection have resulted in remarkable advancements and transformed cancer outcomes for many patients. Given the numerous targeted therapies available against cancer, molecular characterization of tumour biomarkers has become essential for selecting the therapeutic options that offer the best survival outcomes. So far, most studies have evaluated therapeutic outcomes in relation to a single tumour biomarker. In contrast, data on patients with tumours expressing two or more biomarkers are limited. Therefore, this systematic literature review aimed to describe the therapeutic outcome, in terms of survival, in patients with primary lung adenocarcinoma harbouring two or more biomarkers compared to patients with tumours positive for a single biomarker. Methods: A search for cross-sectional observational studies on lung cancer published between January 2017 and December 2021 was conducted in the PubMed, Embase, Cochrane, Lilacs, and Google academic databases. Articles reporting dual biomarker expression were selected according to the Preferred Reporting Items for Systematic Reviews (PRISMA) guideline. Results: Fourteen cross-sectional observational studies were included in the systematic review. Three studies reported survival data in patients with lung cancer positive for a mutated EGFR (epidermal growth factor) and overexpressing PD-L1 (programmed death ligand 1); two studies dealt with cases expressing ALK (anaplastic lymphoma kinase) rearrangements and overexpressing PD-L1; and nine studies concerned patients with concurrent EGFR, ALK, and ROS1 (proto-oncogene 1 ROS1) alterations. On average, progression-free survival was 8.78 months in patients carrying tumours with concomitant biomarker expression and 12.13 months in those with a single biomarker. In addition, overall survival data were 26.07 months and 25.65 months for patients with tumours with dual or single biomarker expression, respectively. Conclusions: Progression-free survival and overall survival were shorter in patients with lung cancer with dual biomarker expression than in cases positive for a single biomarker.
Descripción
Abstract
Introduction: Lung cancer is one of the most prevalent types of malignancy and a leading cause of cancer-related death. Substantial improvements in the understanding of disease biology, the refinement of therapeutic approaches, and the implementation of predictive biomarkers for treatment selection have resulted in remarkable advancements and transformed cancer outcomes for many patients. Given the numerous targeted therapies available against cancer, molecular characterization of tumour biomarkers has become essential for selecting the therapeutic options that offer the best survival outcomes. So far, most studies have evaluated therapeutic outcomes in relation to a single tumour biomarker. In contrast, data on patients with tumours expressing two or more biomarkers are limited. Therefore, this systematic literature review aimed to describe the therapeutic outcome, in terms of survival, in patients with primary lung adenocarcinoma harbouring two or more biomarkers compared to patients with tumours positive for a single biomarker. Methods: A search for cross-sectional observational studies on lung cancer published between January 2017 and December 2021 was conducted in the PubMed, Embase, Cochrane, Lilacs, and Google academic databases. Articles reporting dual biomarker expression were selected according to the Preferred Reporting Items for Systematic Reviews (PRISMA) guideline. Results: Fourteen cross-sectional observational studies were included in the systematic review. Three studies reported survival data in patients with lung cancer positive for a mutated EGFR (epidermal growth factor) and overexpressing PD-L1 (programmed death ligand 1); two studies dealt with cases expressing ALK (anaplastic lymphoma kinase) rearrangements and overexpressing PD-L1; and nine studies concerned patients with concurrent EGFR, ALK, and ROS1 (proto-oncogene 1 ROS1) alterations. On average, progression-free survival was 8.78 months in patients carrying tumours with concomitant biomarker expression and 12.13 months in those with a single biomarker. In addition, overall survival data were 26.07 months and 25.65 months for patients with tumours with dual or single biomarker expression, respectively. Conclusions: Progression-free survival and overall survival were shorter in patients with lung cancer with dual biomarker expression than in cases positive for a single biomarker.
Palabras clave
Receptor del factor de crecimiento epidérmico (EGFR), Linfoma anaplásico quinasa (ALK), Ligando de muerte programada 1 (PD-L1), Adenocarcinoma de pulmón
Keywords
Epidermal growth factor receptor (EGFR), Anaplastic lymphoma kinase (ALK), Programmed death-ligand 1 (PD-L1), Lung adenocarcinoma